Anti-doping comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Early clinical research explored GW501516 for lipid disorders, obesity, and diabetes. Some short-term human studies reported changes in HDL cholesterol, LDL cholesterol, and triglycerides. The development program was discontinued after rodent studies showed dose-dependent tumor formation in multiple tissues, including liver, bladder, stomach, and skin. These findings raised concerns about long-term cancer risk in humans. Because human exposure data are limited, the clinical significance of the rodent tumors remains uncertain.
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ | Nuclear receptor; not androgen receptor |
| Studied indications | Dyslipidemia; obesity; diabetes | Early clinical research; development discontinued |
| Rodent toxicity | Tumor formation in multiple tissues | Dose-dependent findings in some studies |
| Human approval | None | No approved therapeutic use |
| Typical analytical method | LC-MS/MS | Used for identity and quantification |
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Sixty-four countries initially joined; it was ratified and came into force in the US in 1967. The Convention on Psychotropic Substances of 1971 added synthetic, prescription and hallucinogenic drugs. The United Nations Convention Against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988 addressed international drug trafficking and "criminalized the entire drug market chain, from cultivation/production to shipment, sale, and possession." In 1968, President Lyndon B. Johnson (1963–69) decided that the government needed to make an effort to curtail the social unrest that blanketed the country at the time. He focused on illegal drug use, an approach that was in line with expert opinion on the subject at the time. In the 1960s, it was believed that at least half of the crime in the US was drug-related, and this estimate grew as high as 90% in the next decade. He created the Reorganization Plan of 1968 which merged the Bureau of Narcotics and the Bureau of Drug Abuse Control to form the Bureau of Narcotics and Dangerous Drugs within the Department of Justice.
== Honours and legacy == The scientific work of Leonidas Zervas had a global resonance and his contribution was recognised by multiple awards throughout his life. In 1960 he received an honorary doctorate from the University of Basel on the occasion of the university's 500th anniversary, upon recommendation of Hans Erlenmeyer and Nobel laureate Tadeusz Reichstein. In 1969 he was bestowed honorary membership of the American Society of Biological Chemists. In 1976 he was conferred the Order of Scientific Merit (1st class) by the Socialist Republic of Romania. In the same year Zervas was made Foreign Member of the USSR Academy of Sciences, an indication of the great respect for his work in the Eastern Bloc, too. The Max-Bergmann-Kreis company of German peptide chemists planned to present Zervas with the first Max Bergmann golden medal for peptide chemistry in 1980, but his sudden death necessitated a posthumous award ceremony. In honour of Zervas, a commemorative bust has been unveiled in his birthtown Megalopolis in 1991 and the main conference hall of the National Hellenic Research Foundation is called the "Leonidas Zervas amphitheatre". The European Peptide Society has established the Leonidas Zervas Award "in commemoration of his outstanding contributions to peptide science", awarded biennially since 1988. The award is given to the "scientist who has made the most outstanding contributions to the chemistry, biochemistry and/or biology of peptides in the five years preceding the date of selection".
== Background == In the late 1970s, tooth adhesion phosphate monomer 2-methacryloyloxethyl phenyl hydrogen phosphate (Phenyl-P) was developed for tooth-saving restoration techniques. 4-Methacryloyloxyethyl trimellitic acid anhydride (4-META) that adheres to not only tooth structures but also dental alloys, was developed almost at the same time. In order to create adhesive monomers having higher performance, investigation and optimization of adhesive monomer molecular structure was carried out. The results of the experiments have provided adhesive monomers with a more suitable chemical structure, and one of those is MDP.
Stickler syndrome, COL2A1 (75% of Stickler cases) Stickler syndrome, COL11A1 Stickler syndrome, COL11A2 (non-ocular) Stickler syndrome, COL9A1 (recessive variant) Stickler syndrome, COL9A2 (recessive variant) Stickler syndrome, COL9A3 (recessive variant) Stickler Syndrome, LOX3 (Recessive, 7 cases reported) Whether there are two or three types of Stickler syndrome is controversial. Each type is presented here according to the gene involved. The classification of these conditions is changing as researchers learn more about the genetic causes.
Lamina propria: is mimicked by seeding oral fibroblasts, producing extracellular matrix, into a biocompatible (porous) scaffold and culturing them in a fibroblast differentiation medium. Basement membrane: containing type IV collagen, laminin, fibronectin and integrins. Ideally, the basement membrane must contain a lamina lucida and a lamina densa. Stratified squamous epithelium: is simulated by oral keratinocytes cultured in a medium containing keratinocyte growth factors such as the epidermal growth factor (EGF). To obtain the best results, the type and origin of the fibroblasts and keratinocytes used in oral mucosa tissue engineering are important factors to hold into account. Fibroblasts are usually taken from the dermis of the skin or oral mucosa. Kertinocytes can be isolated from different areas of the oral cavity (such as the palate or gingiva). It is important that the fibroblasts and keratinocytes are used in the earliest stage possible as the function of these cells decreases with time. The transplanted keratinocytes and fibroblasts should adapt to their new environment and adopt their function. There is a risk of losing the transplanted tissue if the cells do not adapt properly. This adaptation goes more smoothly when the donor tissue cells resemble the cells of the native tissue.
Sources: en.wikipedia.org
124Xe (n,γ) → 125mXe (57 s) → 125I 124Xe (n,γ) → 125gXe (16.9 h) → 125I The irradiation target is the primordial nuclide 124Xe, which is the target isotope for making 125I by neutron capture. It is loaded into irradiation capsules of the zirconium alloy zircaloy-2 (a corrosion resisting alloy transparent to neutrons) to a pressure of about 100 bar (~ 100 atm). Upon irradiation with slow neutrons in a nuclear reactor, several radioisotopes of xenon are produced. However, only the decay of 125Xe leads to a radioiodine: 125I. The other xenon radioisotopes decay either to stable xenon, or to various caesium isotopes, some of them radioactive (i.e., caesium-135 and caesium-137). Long irradiation times are disadvantageous. Iodine-125 itself has a neutron capture cross section of 900 barns, and consequently during a long irradiation, part of the 125I formed will be converted to 126I, a beta-emitter and positron-emitter with a half-life of 12.93 days, which is not medically useful. In practice, the most useful irradiation time in the reactor amounts to a few days. Thereafter, the irradiated gas is allowed to decay for three or four days to eliminate short-lived unwanted radioisotopes, and to allow the newly produced xenon-125 to decay to iodine-125. To isolate the radioiodine, the irradiated capsule is first cooled at low temperature (to condense the free iodine gas onto the capsule inner wall) and the remaining Xe gas is vented in a controlled way and recovered for further use.
==== Control system ==== Finally, the control system sets up controlled values for shelf temperature, pressure, and time that are dependent on the product and/or the process. The freeze-dryer can run for a few hours or days depending on the product.
Liu had seized the Chengdu Arsenal in 1925 after Yang Sen's downfall, but to appease the city's other warlords, he announced plans to convert it into a mechanical repair shop rather than a weapons factory. To oversee this process, he appointed his brother Liu Wencheng, who had previously run a distillery, as its manager. Liu Wencheng would also later be appointed to several managerial positions in industrial enterprises. The Chengdu Arsenal would eventually be converted into a mint, increasing Liu Wenhui's money supply. Liu's brother Wencheng used his position in Chengdu to purchase houses and land, expanding his family's real estate holdings. He purchased so much property that his rivals nicknamed him "Liu Half-City", implying he owned half of Chengdu. Liu Wenhui's army continued growing due to money and industrial supplies from his brothers. Over the course of 1926, he attacked and disarmed the forces of Yang Chunfang in January and Lü Chao in April, taking control of Lü's territories in southern Sichuan. To formalize the division of Chengdu, Liu, Deng, and Tian established a joint command in December 1926 with Liu as director. In December 1926, communist forces under Liu Bocheng launched the Luzhou Uprising in Sichuan as part of the Northern Expedition. Liu Bocheng's forces successfully took control of the city from warlord Lai Xinhui. Control of Luzhou was coveted by several neighboring warlords, who had also begun besieging the city. To prevent his rivals from capturing Luzhou, Liu dispatched his friend Leng Yingdong to surround the city in April 1927.
A clinical trial produces data that could reveal quantitative differences between two or more interventions; statistical analyses are used to determine whether such differences are true, result from chance, or are the same as no treatment (placebo). Data from a clinical trial accumulate gradually over the trial duration, extending from months to years. Accordingly, results for participants recruited early in the study become available for analysis while subjects are still being assigned to treatment groups in the trial. Early analysis may allow the emerging evidence to assist decisions about whether to stop the study, or to reassign participants to the more successful segment of the trial. Investigators may also want to stop a trial when data analysis shows no treatment effect.
== Further reading == ABC News gallery of Cheese seized by the Dallas ISD Pantazi, Andrew. "‘Cheese’ heroin led Dallas 13-year-old to a life on the edge." The Dallas Morning News. 29 December 2012. Updated 30 December 2012. Dave Montgomery. "Law enforcement worries 'cheese heroin' could spread," McClatchy Newspapers, July 18, 2007. Maxwell, Jane C., PhD (Senior Research Scientist, University of Texas at Austin Gulf Coast Addiction Technology Transfer Center). "“Cheese” Heroin: Status as of May 2, 2007" (Archive) Merlan, Anna. "In Suburban Dallas, Loosening "Cheese" Heroin's Deadly Grip Archived 2013-10-13 at the Wayback Machine." Dallas Observer. July 28, 2011. Merlan, Anna. "Why Does Dallas Keep Forgetting About its Cheese-Heroin Problem? Archived 2012-12-24 at the Wayback Machine" Dallas Observer. May 21, 2012. "Dallas Man Sentenced to a Total of 240 Months in Federal Prison for Role in Heroin Distribution Conspiracies." (Archive[link removed]) United States Department of Justice. November 5, 2013. Tracy Sabo. "Deadly $2 heroin targets teens," CNN, June 12, 2007. "New Drug Hits the Street? A 'Poor Man's Heroin' For Kids", Pine Magazine, June 12, 2007.
Sources: en.wikipedia.org
== History == Golden Harvest InfoTech Limited was established in 2000. It is a software export-oriented company. Golden Harvest started manufacturing frozen food in 2006. Golden Harvest founded Taher Ahmed Choudhury Charitable Hospital in 2006 in Bhadeshwar Union, Golapganj Upazila, Sylhet District. Golden Harvest Developers Limited was established in 2009. In January 2011, Golden Harvest Agro was given an A grade by the British Retail Consortium. Golden Harvest Group established Golden Harvest Foods Limited in 2012 to manufacture snacks such as chips and chanachur. It signed an agreement with Nippon Express to launch a joint venture company in Bangladesh. In October 2012, Golden Harvest Agro Industries received permission for their IPO on the Dhaka Stock Exchange. In 2014, Golden Harvest launched a cold chain network with funding from the United States Agency for International Development (USAID). It also received support from the Cold Chain Bangladesh Alliance. Golden Harvest is a sponsor of Dhaka Art Summit, of which Rajeeb Samdani is the founder. In March 2018, Golden Harvest signed an agreement with Jubilant FoodWorks to launch Domino's Pizza in Bangladesh. The first branch was opened in Dhanmondi on 15 March 2019 under a joint venture company called Jubilant Golden Harvest Limited. During the COVID-19 pandemic in Bangladesh, sales of frozen food increased for Golden Harvest. Frozen Paratha and bread sales increased while frozen snacks such as samosa, sausages and ice cream declined dramatically.
Camping food is food brought on or designed for camping, hiking, and backpacking trips. The term also encompasses ingredients that can be used to make said foods. The primary differences relate to campers' and backpackers' special needs for foods that have appropriate cooking time, perishability, weight, and nutritional content. To address these needs, camping food is often made up of freeze-dried, dehydrated, pre-cooked, pre-prepared, or otherwise preserved foods that can last extended periods.
== External links == (in French) [1] Page consacrée à la 9e BIMa sur le site du Ministère de la Défense Site de la fanfare et du bagad de la 9 L'ordre de bataille de l'armée de terre Archived 21 May 2013 at the Wayback Machine
Robertsonian translocation (ROB) A type of chromosomal translocation by which double-strand breaks at or near the centromeres of two acrocentric chromosomes cause a reciprocal exchange of segments that gives rise to one large metacentric chromosome (composed of the long arms) and one extremely small chromosome (composed of the short arms), the latter of which is often subsequently lost from the cell with little effect because it contains very few genes. The resulting karyotype shows one fewer than the expected total number of chromosomes, because two previously distinct chromosomes have essentially fused together. Carriers of Robertsonian translocations are generally not associated with any phenotypic abnormalities, but do have an increased risk of generating meiotically unbalanced gametes.
Sources: en.wikipedia.org
It targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not act primarily on androgen receptors. This distinction separates it from SARMs.
Rodent studies found dose-dependent tumors in several organs. The sponsor discontinued the program over cancer concerns. Human risk from long-term use remains unknown.
Controlled human endurance trials are lacking. Animal studies show increased exercise capacity under some conditions. Anecdotal reports are not equivalent to clinical evidence.
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.